SciNeuro Pharmaceuticals

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing breakthrough therapies for neurodegenerative diseases. Since its establishment in 2020, SciNeuro has built a series of process programs from discovery to clinical development, focusing on three key disease-driving mechanisms of neurodegeneration—neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatments for Alzheimer's disease, Parkinson's disease, and other serious central nervous system disorders.